Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

X
Trial Profile

A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cedazuridine/decitabine (Primary) ; Venetoclax (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2023 Results (n=39) evaluating the responses of patients treated with DEC-C with Ven according to different response criteria along with cytogenetic responses and mutation dynamics, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results of pooled analysis from NCT04160052, NCT04550442,NCT04655755 ,explaining resistance of GMP pattern and MDS to venetoclax therapy presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 20 Jun 2023 Planned End Date changed from 20 Jul 2023 to 20 Jul 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top